Every comparison of orforglipron and oral semaglutide I have read this year opens with the same move: two percentages, side by side, and a winner. I think that framing is wrong — not slightly, but structurally. It compares numbers that were never designed to be compared, and it ignores the variable that will actually decide which pill reaches more people.
Here is the thesis, stated up front. Orforglipron and oral semaglutide are not competing on efficacy. They are competing on how many doses each company can physically manufacture per kilogram of active ingredient — and on that axis the two molecules are not close, not even in the same order of magnitude. Everything else in the comparison is downstream of that.
This matters because the entire market narrative has been built on the wrong axis. When Lilly reported ATTAIN-1 in August 2025 and the stock fell roughly 14% in a day, the market was grading a small-molecule tablet on an injectable's curve. That was a category error at the time, and repeating it against oral semaglutide compounds it.
The minimum background. Oral semaglutide is the same peptide as injectable semaglutide — Novo Nordisk's molecule, sold as Rybelsus in type 2 diabetes since 2019 and developed at higher strengths for weight management. Because peptides are destroyed in the stomach, the tablet carries an absorption enhancer called SNAC, and even with it, roughly 1% or less of the swallowed dose reaches the bloodstream. Orforglipron, discovered at Chugai and licensed to Lilly, is not a peptide at all. It is a conventional small molecule that binds the same receptor, made by ordinary chemical synthesis and absorbed without an enhancer.
The efficacy comparison everyone runs is statistically invalid
Start with what the numbers actually say, and then with why lining them up is a mistake. In ATTAIN-1, the Phase 3 obesity trial in people without diabetes, orforglipron's top dose produced roughly 12.4% mean weight loss at 72 weeks against about 0.9% on placebo. In ACHIEVE-1, the type 2 diabetes readout from April 2025, A1C fell about 1.3% to 1.6% across doses with roughly 7.9% weight loss at the 36 mg dose over 40 weeks.
Novo's oral semaglutide numbers sit higher. The OASIS program put the 50 mg oral dose at roughly 15.1% mean weight loss at 68 weeks, and the 25 mg dose in the range of 13.6%. Take those two sets of figures at face value and you get the headline everyone wrote: the Novo pill wins by two or three points.
Except that comparison has no statistical standing. ATTAIN-1 and OASIS are separate trials, run by different sponsors, with different enrollment criteria, different baseline weights, different durations — 72 weeks against 68 — different placebo arms, and different geographic mixes. Cross-trial comparison is the oldest bad habit in pharmaceutical journalism, and in this class it has been wrong before: the only reason we know tirzepatide outperforms semaglutide is that SURMOUNT-5 actually put them in the same room. No such trial exists here. Until one does, "15.1% beats 12.4%" is a sentence with the grammar of evidence and none of the substance.
The number that actually separates them
Now the arithmetic I think should lead every one of these comparisons. Injectable semaglutide for weight management is dosed at 2.4 mg once weekly. Oral semaglutide at 25 mg once daily is 175 mg per week of the same peptide. That is roughly seventy times more active ingredient per patient, per week, to treat the same person — a direct consequence of that sub-1% absorption. The pill does not make the molecule cheaper. It makes it dramatically more expensive to supply.
Semaglutide is not a compound you press out of a reactor at will. It is produced through a fermentation-plus-synthesis process that Novo has spent billions expanding — the roughly $4.1 billion North Carolina build-out, the $11 billion move for Catalent fill-finish capacity. Those investments were made because peptide supply is the binding constraint on this entire franchise. An oral formulation that consumes seventy doses' worth of peptide to deliver one week of therapy runs directly into that constraint rather than around it.
Orforglipron has no such ceiling. A small molecule is made by standard chemical synthesis at conventional cost, pressed into tablets, and shipped without a cold chain. The whole point of the molecule is that its supply curve looks like a statin's, not a biologic's.
One pill is a peptide in a costume. The other is a tablet in the ordinary sense of the word. Grading them on the same efficacy scale hides the only difference that scales.
What a percentage cannot capture
There is a second axis the efficacy table also flattens, and it is about the conditions attached to each product rather than the biology. Because SNAC-assisted absorption is fragile, the semaglutide tablet's label carries strict administration conditions — an empty stomach, a small volume of plain water, a waiting interval before anything else. Orforglipron's Phase 3 program was run without food or water restrictions, and that difference is not cosmetic.
I am not making a claim here about what any individual should take; that is a matter between a person and a licensed clinician, and this magazine does not do medical advice. I am making a claim about population-level arithmetic. Any therapy with conditional administration loses a share of its real-world effect to imperfect conditions, and that share is invisible in a controlled trial where adherence is monitored. A drug that is 15% effective under supervision and a drug that is 12% effective under no particular constraint are not separated by three points once you leave the clinic. They may not be separated at all.
The safety column deserves one line, because it is the reason orforglipron exists as a filing candidate at all. Pfizer's oral small-molecule program — lotiglipron, then danuglipron — was effectively ended by liver-enzyme concerns. Orforglipron's Phase 3 readouts have not produced a hepatic signal. Gastrointestinal effects tracked the usual GLP-1 pattern. That clean liver column is worth more than three percentage points of weight loss, and almost nobody puts it in the comparison table.
The counter-argument, taken seriously
The strongest case against me is that efficacy is not a detail — it is the product. In the American market, prescribers and patients choose on the number, payers build formularies around the number, and a pill that delivers two or three fewer points will lose those decisions regardless of how elegantly it is manufactured. If the market only rewards the best result, then manufacturability is a footnote and Novo wins the segment it created.
I take that seriously, with one qualification. It describes the United States, which is about 4% of the world's population and the only large market where obesity therapy is priced as a premium consumer good. In the other 96%, cold chain, unit cost, and volume are not secondary considerations — they are the whole decision. A drug class that cannot be manufactured cheaply at scale does not reach India, Brazil, Indonesia, or most of Europe's public systems in meaningful volume. That is where the seventy-to-one ratio stops being trivia.
The second counter-argument is fairer: Novo has solved harder supply problems than this one, and betting against a company that has been scaling peptide capacity for a decade is a good way to be wrong. True. But solving it means spending capital to overcome a chemical disadvantage that its competitor simply does not have. That is not a level comparison. It is a handicap being absorbed by a balance sheet.
Read the comparison the other way
So here is how I would rewrite every orforglipron-versus-oral-semaglutide piece published this year. Delete the percentages from the headline. They come from non-comparable trials and they measure the thing least in doubt — both molecules work, both produce clinically meaningful weight reduction, and the gap between them is smaller than the error bars on the comparison itself.
Put the manufacturing line in the headline instead. One pill needs roughly seventy times the active ingredient of its own injectable version to do the same job, and is made through one of the most capital-intensive processes in the industry. The other is a tablet made by standard synthesis with no cold chain and no absorption workaround. That is the difference that determines who gets treated, at what price, in how many countries — and it will still be the difference long after the efficacy debate is settled by a head-to-head trial that, as of today, nobody has run.
The most underrated fact in this comparison is that the interesting question was never which pill is stronger. It is which pill can exist in a hundred million medicine cabinets. I think we have been reading the wrong column of the table for a year.
Ozemback — July 2026